The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
出版年份 2010 全文链接
标题
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
作者
关键词
-
出版物
BLOOD
Volume 115, Issue 22, Pages 4478-4487
出版商
American Society of Hematology
发表日期
2010-03-17
DOI
10.1182/blood-2009-12-257261
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress
- (2010) Girija Dasmahapatra et al. CANCER BIOLOGY & THERAPY
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
- (2009) K. Dunleavy et al. BLOOD
- Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells
- (2009) T. Hideshima et al. BLOOD
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes
- (2009) Zhibin Wang et al. CELL
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells
- (2009) S. Bhalla et al. CLINICAL CANCER RESEARCH
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
- (2008) M. Crump et al. ANNALS OF ONCOLOGY
- Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells
- (2008) Y. Dai et al. BLOOD
- Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
- (2008) Deborah J. Kuhn et al. BLOOD
- Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
- (2008) G. Garcia-Manero et al. BLOOD
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
- Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells
- (2008) Y. Dai et al. CLINICAL CANCER RESEARCH
- DNA Replication Arrest in Response to Genotoxic Stress Provokes Early Activation of Stress-Activated Protein Kinases (SAPK/JNK)
- (2008) Julia Damrot et al. JOURNAL OF MOLECULAR BIOLOGY
- Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
- (2008) Roberto R. Rosato et al. MOLECULAR CANCER THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now